EGFR and neoplasm: Erlotinib is a HER1/EGFR-specific reversible TKI that binds to the cytoplasmic ATP pocket domain of the receptor, blocking cell-cycle progression, inducing apoptosis and suppressing the growth of human tumor cell lines and xenografts models in mice (Raizer, 2005; Brandes et al., 2008; Taylor et al., 2012).